CELGENE CORPORATION (NASDAQ:CELG) Files An 8-K Financial Statements and Exhibits
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

CELGENE CORP /DE/ Exhibit
EX-99.1 2 tv494982_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1   CELGENE CORPORATION ANNOUNCES ADDITIONAL $3 BILLION SHARE REPURCHASE AUTHORIZATION AND PLANS TO EXECUTE A $2 BILLION ACCELERATED SHARE REPURCHASE PROGRAM   SUMMIT,…
To view the full exhibit click here

About CELGENE CORPORATION (NASDAQ:CELG)

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.